Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354573 | 0.98 | LPL (0.49) | LPLLIPGALDH1A1MAPTKDM4E | |
| SCHEMBL16922341 | 0.95 | LPL (0.49) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16611249 | 0.87 | LPL (0.42) | LPLLIPGALDH1A1MAPTKDM4E | |
| SCHEMBL138606 | 0.86 | LPL (0.47) | LPLLIPGALDH1A1MAPTKDM4E | |
| SCHEMBL16685004 | 0.85 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19583 | 0.85 | ALDH1A1 (0.49) | LPLLIPGALDH1A1MAPTKDM4E | |
| SCHEMBL17595987 | 0.85 | LPL (0.44) | LPLLIPGALDH1A1MAPTMEN1 | |
| SCHEMBL24266350 | 0.84 | L3MBTL3 (0.61) | LPLLIPGL3MBTL1 | |
| SCHEMBL20644510 | 0.83 | LPL (0.65) | LPLLIPGALDH1A1MAPTKDM4E | |
| SCHEMBL20644595 | 0.83 | MAPT (0.51) | LPLLIPGALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740948-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND | Dong Wha Pharm. Co., Ltd. (KR) | 2026-05-13 | — | — | EP | disclosed |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INST NAT SANTE RECH MED (FR) | 2025-12-18 | — | — | US | disclosed |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| EP-4514780-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | Dong-A ST Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2025-02-20 | — | — | US | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| EP-4464701-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| EP-4460500-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2024-11-13 | — | — | EP | disclosed |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | DONG WHA PHARM. CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | AMR TECHNOLOGY, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | AMR TECHNOLOGY, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | AMR TECHNOLOGY, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009015037-A2 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009015037-A2 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CYP2C9, CYP1B1, SULT1A1 | LPL 2984/4885LIPG 3537/4885ALDH1A1 111/4885 |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | IL5, ACE2, IL15 | LPL 3407/4885LIPG 3149/4885ALDH1A1 525/4885 |
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | BBOX1, NDUFB6, NDUFB5 | LPL 4839/4885LIPG 4884/4885ALDH1A1 108/4885 |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | LPL 3754/4885LIPG 4167/4885ALDH1A1 649/4885 |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | LPL 149/4885LIPG 271/4885ALDH1A1 365/4885 |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | LPL 2217/4885LIPG 2295/4885ALDH1A1 889/4885 |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | CYP3A5, PNPO, NDUFS3 | LPL 4281/4885LIPG 4503/4885ALDH1A1 374/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | LPL 3263/4885LIPG 1906/4885ALDH1A1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.